Injectable or Pill? Year-Long Study Finds Family Caregiver Burden Falls Equally in Schizophrenia

For millions of families living with schizophrenia, the weight of care falls not on clinics but on kitchen tables. Caregivers manage medications, absorb financial strain, and carry the emotional toll of watching a loved one navigate psychosis. A new 48-week prospective cohort study from Guangdong Province, China, now offers a striking and counterintuitive answer to one of psychopharmacology’s most practical questions: does switching from daily pills to long-acting injectable antipsychotics meaningfully ease the burden on families? According to the research, published in BMC Psychiatry, the answer is no—at least not in the structured, fully subsidized community mental health system where the study was conducted.

Long-acting injectable antipsychotics, known as LAIs, have long been promoted as a technological fix for one of schizophrenia treatment’s most stubborn problems: non-adherence. Oral antipsychotics work well when taken consistently, but studies have repeatedly shown that many patients miss doses, stop treatment during relapses, or take medication irregularly. LAIs, administered by injection at intervals ranging from monthly to once every three months, bypass the daily decision to take a pill. The pharmacological logic is straightforward—stable drug levels in the bloodstream should mean fewer relapses, fewer crises, and, by extension, less demand placed on the family members who shoulder the consequences of treatment failure.

The research team, led by Ya-Jun Sun and Yong-Yong Teng of The Third People’s Hospital of Zhuhai, set out to test that logic in a real-world setting rather than a tightly controlled trial. Between April 2023 and December 2024, they enrolled 538 community-dwelling adults with schizophrenia who were receiving routine care through community mental health services in four cities across Guangdong Province. Of these, 270 were receiving long-acting injectable paliperidone palmitate and 268 were on oral antipsychotics. Crucially, patients were not randomized; treatment allocation reflected ordinary clinical decision-making by physicians and patients, which makes the study a portrait of practice as it actually happens. Notably, paliperidone palmitate was fully reimbursed by the government throughout the study period, removing cost as a barrier to injection therapy.

The investigators tracked three intertwined outcomes at five time points across the year. The primary measure was family caregiver burden, assessed with the 24-item Family Burden Interview Schedule, a validated instrument that captures financial strain, disruption of household routines, effects on family leisure and interaction, and the physical and psychological health of caregivers themselves. Alongside it, they measured psychiatric symptoms using the Positive and Negative Syndrome Scale, the standard clinical yardstick for psychosis severity, and social functioning with the Personal and Social Performance Scale, which grades a patient’s capacity for work, relationships, and self-care.

The headline finding is a story of two trajectories that converge. Caregiver burden fell substantially in both groups. In the oral antipsychotic group, adjusted total burden scores dropped from 9.16 to 6.32, a reduction of 31.0 percent. In the injectable group, scores fell from 9.09 to 5.53, a 39.2 percent reduction. On the surface, the injectable group appears to have fared better—but the statistical analysis tells a more careful story. Using linear mixed-effects models, the standard framework for analyzing repeated measurements nested within individuals over time, the team tested whether the two groups followed genuinely different trajectories. After adjusting for multiple comparisons, no treatment-by-time interaction was significant, and the effect sizes were vanishingly small, with Cohen’s f² values at or below 0.003.

The multiplicity-adjusted 95 percent confidence intervals tell the most decisive part of the story. Every one of them lay entirely within a ±2.4-point band around zero difference—the threshold the researchers defined as clinically meaningful on the FBIS-24 scale. In other words, the data were precise enough to rule out a difference that would matter to families. This distinction between statistical noise and clinical relevance is one of the study’s most important technical contributions. A nominal p-value below 0.05 might tempt a less rigorous analysis into declaring victory for injections, but effect sizes near zero and confidence intervals confined to the relevance bound reveal that any apparent advantage is too small for a caregiver to notice in daily life.

The researchers also examined individual burden domains on an exploratory basis. At 48 weeks, three domains—family leisure, family interaction, and the mental health of caregivers—showed nominally significant differences favoring the injectable group. Yet even these signals were negligible in magnitude, with f² values of approximately 0.005, and none survived correction across the full family of exploratory tests. The authors are careful to frame these findings as hypothesis-generating only, a caution that reflects modern standards for controlling false discoveries when many sub-measures are tested simultaneously. Psychiatric symptoms and social functioning improved in both groups over the year, with no detectable differences between formulations, and sensitivity analyses using propensity-score overlap weighting—an approach that reweights the comparison groups to mimic the balance achieved by randomization—reached the same conclusions.

Why might injections fail to outperform pills in this particular context? The study’s setting offers a plausible explanation. All participants were clinically stable adults already embedded in a structured community-based rehabilitation program, with regular contact with mental health services and full government reimbursement removing financial obstacles. In such an environment, the community system itself may be doing the work that injections are supposed to do: ensuring consistent treatment, catching early warning signs, and supporting patients before crises develop. When adherence is actively supported by outreach and supervision, the pharmacological advantage of a depot injection may simply have nothing left to add. The authors explicitly note that the open questions remain whether LAIs would reduce caregiver burden in settings without full subsidy, or among acutely ill or poorly adherent patients—the populations in whom the theoretical advantage of injectables is strongest.

The broader significance of the study lies in where it places the measuring stick. Most trials of antipsychotic formulations focus on relapse rates, hospitalization, or symptom scores—outcomes that matter to clinicians and health systems. By centering family caregiver burden, the Guangdong team highlights an outcome that is often invisible in pharmacological comparisons but dominates the lived experience of schizophrenia, particularly in Asian family systems where caregivers assume substantial financial, physical, and psychosocial responsibilities. Schizophrenia ranks among the leading causes of disability worldwide when measured in disability-adjusted life years, and much of that disability radiates outward from the patient to the household.

For families and clinicians, the practical message is one of reassurance and choice. In a well-supported community mental health program, the choice between a daily pill and a long-acting injection did not change how heavily caregiving weighed on families over the course of a year—both paths led to substantial relief as symptoms improved and functioning recovered. That finding does not render injectables useless; they remain a valuable option for patients who struggle with oral adherence or prefer the convenience of less frequent dosing. But it does suggest that the infrastructure around treatment—consistent contact, structured rehabilitation, and financial access—may matter more to family wellbeing than the formulation inside the syringe or the capsule. As health systems worldwide expand community-based mental health care, this study offers a data-driven reminder that supporting the system may be as powerful as upgrading the drug.

Subject of Research: Comparing family caregiver burden trajectories under long-acting injectable versus oral antipsychotic treatment in community-based schizophrenia rehabilitation

Article Title: No clinically meaningful difference detected in trajectories of family burden in adults with schizophrenia receiving community-based rehabilitation: a 48-week prospective cohort study of long-acting injectable versus oral antipsychotics

Article References: Sun, Y.-J., Teng, Y.-Y., Wang, S.-B., Xie, X.-L., Chen, C., Xie, L.-Y., Li, J.-Y., Huang, J.-J., Mao, C., & Zhang, G.-C. (2026). No clinically meaningful difference detected in trajectories of family burden in adults with schizophrenia receiving community-based rehabilitation: a 48-week prospective cohort study of long-acting injectable versus oral antipsychotics. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08665-y

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08665-y

Keywords: schizophrenia, long-acting injectable antipsychotics, family caregiver burden, community mental health, prospective cohort study, paliperidone palmitate, psychopharmacology, caregiving, psychosis, Guangdong China, medication adherence, BMC Psychiatry